Angelini Pharma celebrates 40 years of eye healthcare with innovative new solutions for glaucoma side effects

On the occasion of the centenary Congress of the Spanish Society of Ophthalmology (SEO), BHH member Angelini Pharma has commemorated its 40 years of dedication to ophthalmology, consolidating its firm commitment to innovation in eye health care. Over four decades, the company has worked on developing advanced solutions to improve the quality of life of patients with eye conditions.

To mark this anniversary, Angelini Pharma has announced the launch of a new solution aimed at reducing the side effects of glaucoma treatment, one of the main causes of irreversible blindness worldwide¹.

The relevance of glaucoma in public health

Glaucoma affects more than 3.5% of the population between 40 and 80 years old¹, representing a major public health issue. Despite its high prevalence, early diagnosis remains complex due to the lack of symptoms in the early stages of the disease, leading many patients to discover it when damage to the optic nerve is already significant¹. By the year 2040, it is estimated that 111.8 million people will suffer from glaucoma, reinforcing the urgent need to improve both early detection and treatment options.

In Spain, approximately one million people, that is, 3% of the population, are affected by this disease, although only half of them are aware of their condition due to the lack of initial symptoms.

New approaches in glaucoma treatment

One of the main challenges in glaucoma treatment is adherence to long-term therapy, largely due to associated side effects. Current treatments, focused on reducing intraocular pressure (IOP) to minimize optic nerve damage and preserve the patient's vision³, can cause bothersome symptoms on the ocular surface, such as dryness, stinging, foreign body sensation, burning, or pain⁴. These effects, many caused by medication preservatives or polypharmacy⁵⁻⁸, negatively impact patients' quality of life, decreasing their adherence to treatment and worsening disease progression.

Aware of this reality, Angelini Pharma has dedicated part of its 40 years in ophthalmic health care to developing solutions that minimize these side effects.

Innovation at the service of well-being

Gemma Malla, Director of the Ophthalmology Unit at Angelini Pharma Spain, highlighted the importance of this approach within the company: "At Angelini Pharma, we believe that innovation in ophthalmology has the power to transform patients' lives. Our purpose is to develop solutions that go beyond treating eye diseases, focusing on improving their quality of life and offering them healthier and fuller vision."

In addition to its advances in ophthalmology, Angelini Pharma has also expanded its focus toward key areas such as neurology, recognizing that eye health is closely linked to Brain Health Care. This interconnection between ophthalmology and neurology has led the company to explore new areas of research that address both ocular and neurological disorders, consolidating its position as a leader in comprehensive health care.

The celebration of these 40 years of innovation represents a key milestone for Angelini Pharma, which remains firm in its commitment to embrace science with passion and develop solutions that respond to the most urgent challenges in the field of eye health. With a patient-centered approach and a comprehensive vision of well-being, the company continues advancing in its mission to offer treatments that significantly improve the lives of those who need them.